21 CFR 213.165
§ 213.165 Testing and release for distribution.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 213.165, § 213.165 Testing and release for distribution, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/86063
- Permanent ID
ys:prov:86063@1- SHA-256
b7eba56ac85cd17e7580c726087148ac17bde3033fae01d138174c6ccfab590e
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) For each batch of medical gas, there shall be appropriate laboratory determination of satisfactory conformance to final specifications for the medical gas, including the identity and strength, prior to release.
(b) Any sampling and testing plans shall be described in written procedures that shall include the method of sampling, the number of units per batch to be tested, and acceptance criteria. Such written procedures shall be followed.
(c) The accuracy, sensitivity, specificity, and reproducibility of test methods employed by the firm shall be established and documented. Such validation and documentation may be accomplished in accordance with § 213.194(a)(2). The suitability of all testing methods shall be verified under actual conditions of use.
(d) Medical gases failing to meet established standards or specifications and any other relevant quality criteria shall be rejected.
(e) This section does not apply to the filling of a designated medical gas or medically appropriate combination of designated medical gases via liquid to liquid into a container at a delivery site.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.